The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Research Report 2025
Synopsis
The global Non-Muscle-Invasive Bladder Cancer Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Muscle-Invasive Bladder Cancer Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Muscle-Invasive Bladder Cancer Treatment.
Report Scope
The Non-Muscle-Invasive Bladder Cancer Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-Muscle-Invasive Bladder Cancer Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Muscle-Invasive Bladder Cancer Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ferring Pharmaceuticals
Merck
Sesen Bio
CG Oncology
ImmunityBio
Theralase
Viventia Bio Inc.
Segment by Type
Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment
Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment
High-Risk Non-Muscle-Invasive Bladder Cancer Treatment
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Muscle-Invasive Bladder Cancer Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Non-Muscle-Invasive Bladder Cancer Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Muscle-Invasive Bladder Cancer Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Muscle-Invasive Bladder Cancer Treatment.
Report Scope
The Non-Muscle-Invasive Bladder Cancer Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-Muscle-Invasive Bladder Cancer Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Muscle-Invasive Bladder Cancer Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ferring Pharmaceuticals
Merck
Sesen Bio
CG Oncology
ImmunityBio
Theralase
Viventia Bio Inc.
Segment by Type
Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment
Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment
High-Risk Non-Muscle-Invasive Bladder Cancer Treatment
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Muscle-Invasive Bladder Cancer Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment
1.2.3 Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment
1.2.4 High-Risk Non-Muscle-Invasive Bladder Cancer Treatment
1.3 Market by Application
1.3.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Perspective (2019-2030)
2.2 Non-Muscle-Invasive Bladder Cancer Treatment Growth Trends by Region
2.2.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non-Muscle-Invasive Bladder Cancer Treatment Historic Market Size by Region (2019-2024)
2.2.3 Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Region (2025-2030)
2.3 Non-Muscle-Invasive Bladder Cancer Treatment Market Dynamics
2.3.1 Non-Muscle-Invasive Bladder Cancer Treatment Industry Trends
2.3.2 Non-Muscle-Invasive Bladder Cancer Treatment Market Drivers
2.3.3 Non-Muscle-Invasive Bladder Cancer Treatment Market Challenges
2.3.4 Non-Muscle-Invasive Bladder Cancer Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Muscle-Invasive Bladder Cancer Treatment Players by Revenue
3.1.1 Global Top Non-Muscle-Invasive Bladder Cancer Treatment Players by Revenue (2019-2024)
3.1.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Muscle-Invasive Bladder Cancer Treatment Revenue
3.4 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Concentration Ratio
3.4.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Muscle-Invasive Bladder Cancer Treatment Revenue in 2023
3.5 Non-Muscle-Invasive Bladder Cancer Treatment Key Players Head office and Area Served
3.6 Key Players Non-Muscle-Invasive Bladder Cancer Treatment Product Solution and Service
3.7 Date of Enter into Non-Muscle-Invasive Bladder Cancer Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Muscle-Invasive Bladder Cancer Treatment Breakdown Data by Type
4.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Historic Market Size by Type (2019-2024)
4.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Type (2025-2030)
5 Non-Muscle-Invasive Bladder Cancer Treatment Breakdown Data by Application
5.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Historic Market Size by Application (2019-2024)
5.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2019-2030)
6.2 North America Non-Muscle-Invasive Bladder Cancer Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024)
6.4 North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2019-2030)
7.2 Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024)
7.4 Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2019-2030)
8.2 Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2019-2030)
9.2 Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024)
9.4 Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2019-2030)
10.2 Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ferring Pharmaceuticals
11.1.1 Ferring Pharmaceuticals Company Detail
11.1.2 Ferring Pharmaceuticals Business Overview
11.1.3 Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Introduction
11.1.4 Ferring Pharmaceuticals Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)
11.1.5 Ferring Pharmaceuticals Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Non-Muscle-Invasive Bladder Cancer Treatment Introduction
11.2.4 Merck Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)
11.2.5 Merck Recent Development
11.3 Sesen Bio
11.3.1 Sesen Bio Company Detail
11.3.2 Sesen Bio Business Overview
11.3.3 Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Introduction
11.3.4 Sesen Bio Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)
11.3.5 Sesen Bio Recent Development
11.4 CG Oncology
11.4.1 CG Oncology Company Detail
11.4.2 CG Oncology Business Overview
11.4.3 CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Introduction
11.4.4 CG Oncology Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)
11.4.5 CG Oncology Recent Development
11.5 ImmunityBio
11.5.1 ImmunityBio Company Detail
11.5.2 ImmunityBio Business Overview
11.5.3 ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Introduction
11.5.4 ImmunityBio Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)
11.5.5 ImmunityBio Recent Development
11.6 Theralase
11.6.1 Theralase Company Detail
11.6.2 Theralase Business Overview
11.6.3 Theralase Non-Muscle-Invasive Bladder Cancer Treatment Introduction
11.6.4 Theralase Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)
11.6.5 Theralase Recent Development
11.7 Viventia Bio Inc.
11.7.1 Viventia Bio Inc. Company Detail
11.7.2 Viventia Bio Inc. Business Overview
11.7.3 Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Introduction
11.7.4 Viventia Bio Inc. Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)
11.7.5 Viventia Bio Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment
Table 3. Key Players of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment
Table 4. Key Players of High-Risk Non-Muscle-Invasive Bladder Cancer Treatment
Table 5. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Region (2019-2024)
Table 9. Global Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Region (2025-2030)
Table 11. Non-Muscle-Invasive Bladder Cancer Treatment Market Trends
Table 12. Non-Muscle-Invasive Bladder Cancer Treatment Market Drivers
Table 13. Non-Muscle-Invasive Bladder Cancer Treatment Market Challenges
Table 14. Non-Muscle-Invasive Bladder Cancer Treatment Market Restraints
Table 15. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Players (2019-2024)
Table 17. Global Top Non-Muscle-Invasive Bladder Cancer Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Muscle-Invasive Bladder Cancer Treatment as of 2023)
Table 18. Ranking of Global Top Non-Muscle-Invasive Bladder Cancer Treatment Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Non-Muscle-Invasive Bladder Cancer Treatment Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Non-Muscle-Invasive Bladder Cancer Treatment Product Solution and Service
Table 22. Date of Enter into Non-Muscle-Invasive Bladder Cancer Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share by Type (2019-2024)
Table 26. Global Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share by Type (2025-2030)
Table 28. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share by Application (2019-2024)
Table 30. Global Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share by Application (2025-2030)
Table 32. North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 47. Ferring Pharmaceuticals Company Detail
Table 48. Ferring Pharmaceuticals Business Overview
Table 49. Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Product
Table 50. Ferring Pharmaceuticals Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024) & (US$ Million)
Table 51. Ferring Pharmaceuticals Recent Development
Table 52. Merck Company Detail
Table 53. Merck Business Overview
Table 54. Merck Non-Muscle-Invasive Bladder Cancer Treatment Product
Table 55. Merck Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024) & (US$ Million)
Table 56. Merck Recent Development
Table 57. Sesen Bio Company Detail
Table 58. Sesen Bio Business Overview
Table 59. Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Product
Table 60. Sesen Bio Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024) & (US$ Million)
Table 61. Sesen Bio Recent Development
Table 62. CG Oncology Company Detail
Table 63. CG Oncology Business Overview
Table 64. CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Product
Table 65. CG Oncology Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024) & (US$ Million)
Table 66. CG Oncology Recent Development
Table 67. ImmunityBio Company Detail
Table 68. ImmunityBio Business Overview
Table 69. ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Product
Table 70. ImmunityBio Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024) & (US$ Million)
Table 71. ImmunityBio Recent Development
Table 72. Theralase Company Detail
Table 73. Theralase Business Overview
Table 74. Theralase Non-Muscle-Invasive Bladder Cancer Treatment Product
Table 75. Theralase Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024) & (US$ Million)
Table 76. Theralase Recent Development
Table 77. Viventia Bio Inc. Company Detail
Table 78. Viventia Bio Inc. Business Overview
Table 79. Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Product
Table 80. Viventia Bio Inc. Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024) & (US$ Million)
Table 81. Viventia Bio Inc. Recent Development
Table 82. Research Programs/Design for This Report
Table 83. Key Data Information from Secondary Sources
Table 84. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Type: 2023 VS 2030
Figure 3. Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment Features
Figure 4. Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment Features
Figure 5. High-Risk Non-Muscle-Invasive Bladder Cancer Treatment Features
Figure 6. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Application: 2023 VS 2030
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Others Case Studies
Figure 11. Non-Muscle-Invasive Bladder Cancer Treatment Report Years Considered
Figure 12. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Region: 2023 VS 2030
Figure 15. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Players in 2023
Figure 16. Global Top Non-Muscle-Invasive Bladder Cancer Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Muscle-Invasive Bladder Cancer Treatment as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Non-Muscle-Invasive Bladder Cancer Treatment Revenue in 2023
Figure 18. North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Country (2019-2030)
Figure 20. United States Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Country (2019-2030)
Figure 24. Germany Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Region (2019-2030)
Figure 32. China Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Country (2019-2030)
Figure 40. Mexico Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Country (2019-2030)
Figure 44. Turkey Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Ferring Pharmaceuticals Revenue Growth Rate in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)
Figure 47. Merck Revenue Growth Rate in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)
Figure 48. Sesen Bio Revenue Growth Rate in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)
Figure 49. CG Oncology Revenue Growth Rate in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)
Figure 50. ImmunityBio Revenue Growth Rate in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)
Figure 51. Theralase Revenue Growth Rate in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)
Figure 52. Viventia Bio Inc. Revenue Growth Rate in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
